Which combinations make rational sense and which might see action in the clinic?
Early stage oncology new product development is a rather strange beast at times. On the one hand is the…
Will degrading BTK work – even in patients who received prior inhibitor therapy?
Finding the sweet spot between safety and activity
An early stage landscape to watch out for with key changes happening in 2024
It's time to start pointing the way for new directions in the Menin niche
What's next beyond BTK inhibition in lymphomas and CLL?
From CAR-T cells to protein degradation
Do we need to pay more attention to the underlying biology in aggressive lymphomas?
Encouraging new developments in the CAR-NK niche
From autologous to gene edited CARs and much in between - W2W4 on 14 next gen products
Exploring future IO-IO combination strategies and life cycle management
What can we learn from the data on inhibitory checkpoints not named PD(L)1 or TIGIT?
Round-up of key highlights relating to CAR-T cell therapies, CELMoDs and super-enhancer activity in DLBCL
A look at two under the radar early developments in lymphomas which might have a shot at approval
A look at 6 IO products in the Heme space and what to watch out for.
Some intriguing new developments in DLBCL to watch out for
